Sector News

Ferring appoints Aaron Graff to Executive Board

June 2, 2017
Life sciences

Ferring Pharmaceuticals announced today that Aaron Graff has been appointed Executive Vice President and Chief Commercial Officer and made a member of the Ferring Group Executive Board, effective immediately.

Aaron Graff joined Ferring in 2002 as Vice President Global Marketing, Business Development, and Medical Affairs, based in Copenhagen, Denmark. After leading the acquisition and integration of Israeli biopharmaceutical company BTG in 2005, he relocated his team to the newly established Ferring International Center in Saint-Prex, Switzerland, where he was promoted to Senior Vice President, Asia Region and Global Marketing. Since 2010, Graff has led Ferring’s U.S. operations from its U.S headquarters in New Jersey, first as Chief Operating Officer and since 2016 as Chief Executive Officer.

“Under Aaron’s leadership in the United States, our U.S. business grew at double-digit rates,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals. “His broad, global professional experience and track record make him uniquely qualified for this important role.”

Prior to joining Ferring, Graff worked at Bristol-Myers Squibb for over 17 years in a variety of sales, marketing and commercial operations management positions.

Source: Ferring Pharmaceuticals

comments closed

Related News

March 19, 2023

Ferring Pharmaceuticals’ 1st in class C.diff Treatment, Rebyota, experiences a positive early launch ahead of potential competition

Life sciences

With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.

March 19, 2023

UCB enters drug discovery collaboration with Aitia

Life sciences

Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.

March 19, 2023

Novo, Medtronic add $25M in fuel to FIRE1 and its heart failure monitoring device

Life sciences

Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.

How can we help you?

We're easy to reach